

**EUROPEAN  
CURRICULUM VITAE  
FORMAT**



**PERSONAL INFORMATION**

Name **SILVIA FINOTTO**  
Address Istituto Oncologico Veneto I.R.C.C.S.  
Medical Oncology 1 Unit  
Via Gattamelata 64  
35128 Padova, ITALY  
Telephone +39-049-8215621  
Fax +39-049-8215900  
E-mail [silvia.finotto@ioveneto.it](mailto:silvia.finotto@ioveneto.it)  
Nationality Italian  
Date of birth 03-03-1978

**WORK EXPERIENCE**

- Dates (from – to) May 2014-present
- Name and address of employer Medical Oncology 1 Unit  
Istituto Oncologico Veneto I.R.C.C.S., Padua  
Public Hospital  
Freelance Medical Hematologist with fixed-term contract  
Medical treatment of onco-hematologic patients and patients undergoing autologous bone marrow transplantation. Research activity in onco-hematological diseases and co-investigator in trials dealing with non-Hodgkin lymphoma.
- Type of business or sector
- Occupation or position held
- Main activities and responsibilities
  
- Dates (from – to) June 2012- May 2014
- Name and address of employer Hematology Operative Unit  
Ospedale San Bortolo, Vicenza  
Public Hospital  
Freelance Medical Hematologist with fixed-term contract  
Medical treatment of hematologic patients, including patients undergoing autologous and allogenic bone marrow transplantation. Research activity in onco-hematological diseases.  
Co-investigator for more than 10 trials (Industry-sponsored and not-sponsored) dealing with myelodysplastic syndromes, non Hodgkin lymphoma, multiple myeloma, chronic myeloid leukemia.
- Type of business or sector
- Occupation or position held
- Main activities and responsibilities

**EDUCATION AND TRAINING**

- Dates (from – to) 2012
- Name and type of organisation providing education and training Residency school in Hematology  
University of Verona, Italy  
Clinical and Laboratory Hematology
- Principal subjects/occupational skills covered
- Title of qualification awarded Medical and Laboratory Hematology Specialty

<ul style="list-style-type: none"> <li>• Dates (from – to)</li> <li>• Name and type of organisation providing education and training</li> <li>• Principal subjects/occupational skills covered</li> <li>• Title of qualification awarded</li> </ul>	<p>2006</p> <p>University of Padua, Italy</p> <p>Medicine</p> <p>Degree in Medicine and Surgery (M.D. Medical Doctor)</p>
---	---

## **PERSONAL SKILLS AND COMPETENCES**

*Acquired in the course of life and career but not necessarily covered by formal certificates and diplomas.*

MOTHER TONGUE

**ITALIAN**

OTHER LANGUAGES

**English**

Good

Good

Good

**ANNEXES**

Publications

- **Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia.** Vannucchi AM, Antonioli E, Guglielmelli P, Pancrazi A, Guerini V, Barosi G, Ruggeri M, Specchia G, Lo-Coco F, Delaini F, Villani L, Finotto S, Ammatuna E, Alterini R, Carrai V, Capaccioli G, Di Lollo S, Liso V, Rambaldi A, Bosi A, Barbui T. Blood 2008. 112(3): 844-7.
- **Treatment outcome in a cohort of young patients with polycythemia vera.** Ruggeri M, Finotto S, Fortuna S, Rodeghiero F. Intern. Emerg. Med. 2010. 5(5); 411-13.
- **Analysis of the oxygen sensing pathway genes in familial chronic myeloproliferative neoplasms and identification of a novel EGLN1 germ-line mutation.** Albiero E, Ruggeri M, Fortuna S, Finotto S, Bernardi M, Madeo D, Rodeghiero F. Br J Haematol 2011. 153 (3): 405-8.
- **Isolated erythrocytosis: study of 67 patients and identification of three novel germ-line mutations in the prolyl hydroxylase domain protein 2 (PHD2) gene.** Albiero E, Ruggeri M, Fortuna S, Finotto S, Bernardi M, Madeo D, Rodeghiero F. Haematologica 2012. 97 (1): 123-127.
- **Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia.** Visco C, Moretta F, Falisi E, Facco M, Maura F, Novella E, Nichele I, Finotto S, Giaretta I, Ave E, Perbellini O, Guercini N, Scupoli MT, Trentin L, Trimarco V, Neri A, Semenzato G, Rodeghiero F, Pizzolo G, Ambrosetti A. Am J Hematol. 2013 Apr;88(4):277-82.
- **The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia.** Visco C, Finotto S, Pomponi F, Sartori R, Laveder F, Trentin L, Paolini R, Di Bona E, Ruggeri M, Rodeghiero F. Am J Hematol. 2013 Apr;88(4):289-93.
- **Combination of Rituximab, Bendamustine, and Cytarabine for Patients With Mantle-Cell Non-Hodgkin Lymphoma Ineligible for Intensive Regimens or Autologous Transplantation.** Visco C, Finotto S, Zambello R, Paolini R, Menin A, Zanotti R, Zaja F, Semenzato G, Pizzolo G, D'Amore ES, Rodeghiero F. J Clin Oncol. 2013 Apr 10;31(11):1442-9.
- **B-cell receptor configuration and mutational analysis of patients with chronic lymphocytic leukaemia and trisomy 12 reveal recurrent molecular abnormalities.** Falisi E, Novella E, Visco C, Guercini N, Maura F, Giaretta I, Pomponi F, Nichele I, Finotto S, Montaldi A, Neri A, Rodeghiero F. Hematol Oncol. 2014 Mar;32(1):22-30.
- **Autoimmune cytopenias in chronic lymphocytic leukemia at disease presentation in the modern treatment era: is stage C always stage C?** Visco C, Cortelezzi A, Moretta F, Falisi E, Maura F, Finotto S, Barcellini W, Ambrosetti A, Neri A, Ruggeri M, Rodeghiero F. Leuk Lymphoma. 2013 Sep 23.
- **Clinical significance of LAIR1 (CD305) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia.** Perbellini O, Falisi E, Giaretta I, Boscaro E, Novella E, Facco M, Fortuna S, Finotto S, Amati E, Maniscalco F, Montaldi A, Alghisi A, Aprili F, Bonaldi L, Paolini R, Scupoli MT, Trentin L, Ambrosetti A, Semenzato G, Pizzolo G, Rodeghiero F, Visco C. Haematologica. 2014 May;99(5):881-7
- **Hepatitis C virus and diffuse large B-cell lymphoma: pathogenesis, behaviour and treatment.** Visco C, Finotto S. World J Gastroenterol. 2014 20(32): 11054-11061.